Lotus Pharmaceuticals, Inc. (LTUS)

Lotus Pharmaceuticals, Inc. (LTUS) — VMCI valuation read

Lotus Pharmaceuticals, Inc. sits at VMCI 31/100, with the Financial Services sector median at 50. That 19-point spread is the first thing to note on LTUS: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on LTUS are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on LTUS: LTUS trades at 18.0x earnings, 0% above the Financial Services median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 16.0% sits 6.0pp above the Financial Services median (10.0%). The Risk read: net debt to EBITDA of 2.0x is the rate-sensitivity line to watch, anchoring the bear scenario on a measurable balance-sheet metric.

LTUS fell 2.4% over the trailing 7 days, with a -5.9% read on a 30-day basis.